| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 50 | 2022 | 696 | 10.210 |
Why?
|
| Malaria | 16 | 2015 | 17 | 4.640 |
Why?
|
| Anti-Retroviral Agents | 14 | 2017 | 80 | 3.530 |
Why?
|
| Antimalarials | 13 | 2015 | 14 | 3.000 |
Why?
|
| Adult | 74 | 2025 | 7678 | 2.590 |
Why?
|
| Young Adult | 50 | 2025 | 2461 | 2.390 |
Why?
|
| Male | 75 | 2025 | 10106 | 2.340 |
Why?
|
| United States | 50 | 2022 | 4003 | 2.310 |
Why?
|
| Adolescent | 54 | 2025 | 3685 | 2.280 |
Why?
|
| Anti-HIV Agents | 8 | 2017 | 155 | 2.240 |
Why?
|
| Sexual Behavior | 10 | 2017 | 124 | 2.240 |
Why?
|
| Middle Aged | 61 | 2025 | 7988 | 2.230 |
Why?
|
| Humans | 99 | 2025 | 17762 | 2.210 |
Why?
|
| Health Personnel | 7 | 2017 | 125 | 2.190 |
Why?
|
| Female | 75 | 2025 | 12740 | 2.160 |
Why?
|
| Cross-Sectional Studies | 28 | 2024 | 1330 | 1.860 |
Why?
|
| Malaria, Falciparum | 10 | 2019 | 10 | 1.850 |
Why?
|
| Medication Adherence | 8 | 2017 | 245 | 1.850 |
Why?
|
| Viral Load | 15 | 2021 | 135 | 1.670 |
Why?
|
| Public Health Surveillance | 4 | 2015 | 42 | 1.550 |
Why?
|
| Artemisinins | 7 | 2014 | 7 | 1.500 |
Why?
|
| Health Facilities | 6 | 2014 | 17 | 1.430 |
Why?
|
| Population Surveillance | 11 | 2019 | 264 | 1.320 |
Why?
|
| Pyrimethamine | 6 | 2015 | 6 | 1.300 |
Why?
|
| Sulfadoxine | 6 | 2015 | 6 | 1.300 |
Why?
|
| Parasitemia | 8 | 2015 | 8 | 1.270 |
Why?
|
| Continuity of Patient Care | 6 | 2017 | 105 | 1.230 |
Why?
|
| Latent Tuberculosis | 4 | 2022 | 10 | 1.210 |
Why?
|
| Delivery of Health Care | 3 | 2017 | 415 | 1.200 |
Why?
|
| Risk-Taking | 7 | 2015 | 109 | 1.190 |
Why?
|
| Ethanolamines | 4 | 2013 | 4 | 1.190 |
Why?
|
| Fluorenes | 4 | 2013 | 5 | 1.180 |
Why?
|
| Prevalence | 18 | 2024 | 886 | 1.150 |
Why?
|
| Tuberculosis | 3 | 2025 | 23 | 1.140 |
Why?
|
| Malawi | 15 | 2019 | 15 | 1.090 |
Why?
|
| Counseling | 5 | 2015 | 189 | 1.070 |
Why?
|
| Risk Reduction Behavior | 4 | 2017 | 108 | 1.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 4 | 2014 | 93 | 1.030 |
Why?
|
| Aged | 26 | 2025 | 6150 | 1.030 |
Why?
|
| Case Management | 5 | 2014 | 32 | 1.010 |
Why?
|
| Time-to-Treatment | 3 | 2021 | 19 | 1.010 |
Why?
|
| Patient Acceptance of Health Care | 5 | 2015 | 390 | 0.990 |
Why?
|
| Insecticides | 3 | 2012 | 7 | 0.990 |
Why?
|
| Immune Evasion | 1 | 2025 | 1 | 0.980 |
Why?
|
| Genome, Viral | 1 | 2025 | 5 | 0.980 |
Why?
|
| Mass Screening | 5 | 2025 | 677 | 0.960 |
Why?
|
| Pregnancy Complications, Parasitic | 2 | 2015 | 4 | 0.940 |
Why?
|
| Child, Preschool | 21 | 2019 | 1419 | 0.940 |
Why?
|
| Disease Transmission, Infectious | 2 | 2015 | 13 | 0.940 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2024 | 4 | 0.930 |
Why?
|
| Antibodies, Viral | 1 | 2024 | 65 | 0.890 |
Why?
|
| Insecticide-Treated Bednets | 2 | 2015 | 2 | 0.890 |
Why?
|
| Hospitalization | 9 | 2021 | 808 | 0.790 |
Why?
|
| Child | 17 | 2024 | 2491 | 0.780 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 6 | 2013 | 52 | 0.780 |
Why?
|
| Sexual and Gender Minorities | 2 | 2019 | 27 | 0.770 |
Why?
|
| Socioeconomic Factors | 5 | 2017 | 630 | 0.770 |
Why?
|
| CD4 Lymphocyte Count | 8 | 2016 | 178 | 0.770 |
Why?
|
| Pneumonia, Viral | 4 | 2021 | 56 | 0.740 |
Why?
|
| Drug Resistance | 3 | 2015 | 31 | 0.740 |
Why?
|
| Ambulatory Care Facilities | 3 | 2015 | 69 | 0.730 |
Why?
|
| Patient Compliance | 2 | 2014 | 300 | 0.730 |
Why?
|
| Diagnostic Tests, Routine | 4 | 2014 | 20 | 0.730 |
Why?
|
| Plasmodium falciparum | 8 | 2019 | 8 | 0.700 |
Why?
|
| Life Expectancy | 1 | 2020 | 33 | 0.700 |
Why?
|
| Influenza, Human | 6 | 2013 | 265 | 0.690 |
Why?
|
| Unsafe Sex | 2 | 2017 | 19 | 0.680 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2022 | 63 | 0.680 |
Why?
|
| HIV | 1 | 2019 | 26 | 0.660 |
Why?
|
| Bisexuality | 1 | 2019 | 12 | 0.650 |
Why?
|
| Patient Care | 1 | 2019 | 35 | 0.650 |
Why?
|
| Homosexuality, Male | 6 | 2019 | 38 | 0.650 |
Why?
|
| Pandemics | 7 | 2022 | 287 | 0.640 |
Why?
|
| Prisons | 2 | 2016 | 29 | 0.640 |
Why?
|
| Infant | 14 | 2019 | 1192 | 0.640 |
Why?
|
| Drug Combinations | 9 | 2015 | 41 | 0.620 |
Why?
|
| Cost of Illness | 2 | 2014 | 92 | 0.620 |
Why?
|
| Infant, Newborn | 11 | 2020 | 855 | 0.600 |
Why?
|
| Data Collection | 3 | 2014 | 256 | 0.600 |
Why?
|
| Health Services Needs and Demand | 3 | 2017 | 93 | 0.590 |
Why?
|
| Bedding and Linens | 2 | 2008 | 4 | 0.590 |
Why?
|
| Models, Statistical | 2 | 2015 | 178 | 0.570 |
Why?
|
| Aged, 80 and over | 11 | 2024 | 1923 | 0.570 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2016 | 4 | 0.550 |
Why?
|
| Emigrants and Immigrants | 2 | 2017 | 27 | 0.550 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2016 | 17 | 0.540 |
Why?
|
| Condoms | 2 | 2017 | 33 | 0.540 |
Why?
|
| Health Services | 1 | 2017 | 112 | 0.540 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 11 | 0.520 |
Why?
|
| Protozoan Proteins | 5 | 2019 | 5 | 0.520 |
Why?
|
| Financial Management | 1 | 2015 | 3 | 0.510 |
Why?
|
| Betacoronavirus | 2 | 2020 | 35 | 0.510 |
Why?
|
| Multilevel Analysis | 1 | 2015 | 12 | 0.510 |
Why?
|
| Papanicolaou Test | 1 | 2015 | 37 | 0.510 |
Why?
|
| Public Health Practice | 1 | 2015 | 13 | 0.510 |
Why?
|
| Financing, Government | 1 | 2015 | 28 | 0.500 |
Why?
|
| Vaginal Smears | 1 | 2015 | 48 | 0.500 |
Why?
|
| Prisoners | 1 | 2016 | 54 | 0.500 |
Why?
|
| Sexually Transmitted Diseases, Bacterial | 1 | 2015 | 3 | 0.490 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 49 | 0.490 |
Why?
|
| Sexually Transmitted Diseases | 1 | 2015 | 54 | 0.490 |
Why?
|
| Disabled Persons | 1 | 2015 | 35 | 0.490 |
Why?
|
| Anemia | 2 | 2012 | 34 | 0.480 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 42 | 0.480 |
Why?
|
| Sexual Partners | 2 | 2017 | 37 | 0.480 |
Why?
|
| Insurance, Health | 1 | 2016 | 183 | 0.480 |
Why?
|
| Transgender Persons | 1 | 2015 | 38 | 0.480 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 568 | 0.480 |
Why?
|
| Plasmodium | 3 | 2011 | 3 | 0.470 |
Why?
|
| Pregnancy | 10 | 2015 | 1524 | 0.470 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2014 | 331 | 0.460 |
Why?
|
| Medicaid | 1 | 2015 | 190 | 0.460 |
Why?
|
| Withholding Treatment | 1 | 2014 | 26 | 0.450 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 125 | 0.450 |
Why?
|
| Placenta | 1 | 2013 | 20 | 0.430 |
Why?
|
| Physicians | 1 | 2014 | 137 | 0.430 |
Why?
|
| Health Education | 1 | 2014 | 111 | 0.430 |
Why?
|
| Obesity | 2 | 2020 | 842 | 0.430 |
Why?
|
| Reagent Kits, Diagnostic | 3 | 2010 | 10 | 0.430 |
Why?
|
| Emergency Service, Hospital | 1 | 2016 | 368 | 0.430 |
Why?
|
| European Continental Ancestry Group | 6 | 2017 | 529 | 0.410 |
Why?
|
| Depression | 2 | 2015 | 505 | 0.410 |
Why?
|
| Treatment Outcome | 9 | 2016 | 1260 | 0.410 |
Why?
|
| Tanzania | 6 | 2013 | 6 | 0.410 |
Why?
|
| Pyrethrins | 1 | 2012 | 2 | 0.410 |
Why?
|
| Nitriles | 1 | 2012 | 7 | 0.400 |
Why?
|
| Smoking | 1 | 2015 | 483 | 0.390 |
Why?
|
| Quality of Health Care | 2 | 2014 | 326 | 0.390 |
Why?
|
| Pregnancy Outcome | 1 | 2013 | 156 | 0.390 |
Why?
|
| Hispanic Americans | 5 | 2017 | 404 | 0.390 |
Why?
|
| Retrospective Studies | 6 | 2025 | 2461 | 0.390 |
Why?
|
| Primary Health Care | 1 | 2017 | 769 | 0.380 |
Why?
|
| Insurance Coverage | 5 | 2016 | 106 | 0.380 |
Why?
|
| California | 7 | 2025 | 2326 | 0.370 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2025 | 379 | 0.360 |
Why?
|
| Comorbidity | 9 | 2021 | 597 | 0.350 |
Why?
|
| African Americans | 5 | 2017 | 472 | 0.350 |
Why?
|
| Risk Factors | 8 | 2025 | 3356 | 0.340 |
Why?
|
| Antiviral Agents | 5 | 2021 | 95 | 0.340 |
Why?
|
| Age Factors | 5 | 2020 | 918 | 0.320 |
Why?
|
| Time Factors | 4 | 2019 | 1093 | 0.320 |
Why?
|
| Sex Factors | 4 | 2020 | 644 | 0.310 |
Why?
|
| Continental Population Groups | 6 | 2017 | 302 | 0.310 |
Why?
|
| Interviews as Topic | 5 | 2014 | 305 | 0.290 |
Why?
|
| Pregnancy Complications, Infectious | 4 | 2015 | 146 | 0.290 |
Why?
|
| African Continental Ancestry Group | 3 | 2017 | 162 | 0.280 |
Why?
|
| Dihydropteroate Synthase | 3 | 2015 | 3 | 0.280 |
Why?
|
| Antigens, Protozoan | 3 | 2019 | 3 | 0.280 |
Why?
|
| Polymerase Chain Reaction | 3 | 2015 | 49 | 0.270 |
Why?
|
| Rural Population | 3 | 2012 | 52 | 0.260 |
Why?
|
| Age Distribution | 4 | 2015 | 246 | 0.260 |
Why?
|
| Regional Health Planning | 1 | 2025 | 6 | 0.250 |
Why?
|
| Poverty | 2 | 2017 | 167 | 0.240 |
Why?
|
| Healthcare Disparities | 4 | 2016 | 203 | 0.240 |
Why?
|
| Fatigue Syndrome, Chronic | 1 | 2024 | 4 | 0.240 |
Why?
|
| Infant, Low Birth Weight | 2 | 2015 | 35 | 0.230 |
Why?
|
| Seroepidemiologic Studies | 1 | 2024 | 18 | 0.230 |
Why?
|
| Mutation | 1 | 2025 | 130 | 0.230 |
Why?
|
| Health Promotion | 1 | 2007 | 281 | 0.230 |
Why?
|
| Mosquito Control | 2 | 2015 | 2 | 0.230 |
Why?
|
| HIV-1 | 4 | 2017 | 70 | 0.220 |
Why?
|
| Social Support | 2 | 2015 | 206 | 0.220 |
Why?
|
| Cardiovascular Diseases | 2 | 2021 | 599 | 0.210 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 37 | 0.200 |
Why?
|
| Critical Care | 3 | 2012 | 71 | 0.200 |
Why?
|
| Substance-Related Disorders | 3 | 2016 | 434 | 0.200 |
Why?
|
| Guideline Adherence | 2 | 2017 | 157 | 0.200 |
Why?
|
| Vaccination | 2 | 2024 | 655 | 0.200 |
Why?
|
| Logistic Models | 2 | 2015 | 927 | 0.200 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 53 | 0.200 |
Why?
|
| Adenosine Monophosphate | 1 | 2021 | 4 | 0.200 |
Why?
|
| Alanine | 1 | 2021 | 6 | 0.200 |
Why?
|
| Financing, Personal | 1 | 2002 | 20 | 0.200 |
Why?
|
| Health Care Reform | 1 | 2002 | 31 | 0.200 |
Why?
|
| Health Services Research | 2 | 2014 | 231 | 0.190 |
Why?
|
| Family Characteristics | 2 | 2012 | 55 | 0.190 |
Why?
|
| Genotyping Techniques | 2 | 2019 | 26 | 0.190 |
Why?
|
| Fever | 4 | 2022 | 55 | 0.190 |
Why?
|
| Animals | 4 | 2007 | 261 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2022 | 2586 | 0.180 |
Why?
|
| Eicosapentaenoic Acid | 1 | 2021 | 9 | 0.180 |
Why?
|
| Health Expenditures | 1 | 2002 | 75 | 0.180 |
Why?
|
| Sex Distribution | 3 | 2017 | 190 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 24 | 0.180 |
Why?
|
| Health Services Accessibility | 3 | 2017 | 292 | 0.180 |
Why?
|
| Matched-Pair Analysis | 1 | 2020 | 10 | 0.180 |
Why?
|
| Causality | 1 | 2020 | 40 | 0.180 |
Why?
|
| Risk Assessment | 3 | 2020 | 1101 | 0.170 |
Why?
|
| Atherosclerosis | 1 | 2021 | 53 | 0.170 |
Why?
|
| Program Evaluation | 3 | 2015 | 223 | 0.170 |
Why?
|
| Ethnic Groups | 4 | 2016 | 485 | 0.170 |
Why?
|
| Mortality | 1 | 2020 | 118 | 0.170 |
Why?
|
| Heterosexuality | 1 | 2019 | 9 | 0.160 |
Why?
|
| Self Disclosure | 1 | 2019 | 22 | 0.160 |
Why?
|
| Behavior | 1 | 2019 | 18 | 0.160 |
Why?
|
| Incidence | 3 | 2022 | 1266 | 0.160 |
Why?
|
| Merozoite Surface Protein 1 | 1 | 2019 | 1 | 0.160 |
Why?
|
| Self Report | 3 | 2017 | 253 | 0.160 |
Why?
|
| Dopamine | 1 | 1998 | 1 | 0.160 |
Why?
|
| Sexuality | 2 | 2016 | 11 | 0.160 |
Why?
|
| Preventive Health Services | 1 | 2020 | 160 | 0.160 |
Why?
|
| Motor Neurons | 1 | 1998 | 8 | 0.160 |
Why?
|
| Tetrahydrofolate Dehydrogenase | 2 | 2015 | 2 | 0.160 |
Why?
|
| Health Status Disparities | 3 | 2016 | 146 | 0.150 |
Why?
|
| Behavioral Risk Factor Surveillance System | 2 | 2015 | 12 | 0.150 |
Why?
|
| Educational Status | 2 | 2017 | 200 | 0.150 |
Why?
|
| Needs Assessment | 2 | 2015 | 69 | 0.150 |
Why?
|
| Sensitivity and Specificity | 6 | 2019 | 304 | 0.150 |
Why?
|
| Financial Support | 1 | 2017 | 5 | 0.150 |
Why?
|
| Internal-External Control | 1 | 2017 | 12 | 0.150 |
Why?
|
| Nurse Practitioners | 1 | 2017 | 19 | 0.150 |
Why?
|
| Social Stigma | 1 | 2017 | 19 | 0.140 |
Why?
|
| Urological Agents | 1 | 2017 | 2 | 0.140 |
Why?
|
| Erectile Dysfunction | 1 | 2017 | 24 | 0.140 |
Why?
|
| Kidney Failure, Chronic | 1 | 2018 | 147 | 0.140 |
Why?
|
| Qualitative Research | 2 | 2015 | 256 | 0.140 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2016 | 14 | 0.130 |
Why?
|
| Health Care Surveys | 2 | 2011 | 230 | 0.130 |
Why?
|
| Patient Participation | 1 | 2017 | 134 | 0.130 |
Why?
|
| Drug Prescriptions | 1 | 2017 | 151 | 0.130 |
Why?
|
| Respiratory Distress Syndrome, Adult | 2 | 2012 | 9 | 0.130 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 28 | 0.130 |
Why?
|
| Asymptomatic Infections | 1 | 2015 | 5 | 0.120 |
Why?
|
| Domestic Violence | 1 | 2015 | 8 | 0.120 |
Why?
|
| Drug Therapy, Combination | 2 | 2012 | 114 | 0.120 |
Why?
|
| Nutrition Surveys | 1 | 2015 | 61 | 0.120 |
Why?
|
| Binge Drinking | 1 | 2015 | 8 | 0.120 |
Why?
|
| Kenya | 3 | 2009 | 5 | 0.120 |
Why?
|
| Body Mass Index | 2 | 2020 | 964 | 0.120 |
Why?
|
| Parity | 1 | 2015 | 74 | 0.120 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 7 | 0.120 |
Why?
|
| Patient Care Management | 1 | 2015 | 30 | 0.120 |
Why?
|
| Homeless Persons | 1 | 2015 | 26 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2015 | 21 | 0.120 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2015 | 33 | 0.120 |
Why?
|
| Specimen Handling | 1 | 2014 | 20 | 0.120 |
Why?
|
| Asthma | 2 | 2020 | 385 | 0.120 |
Why?
|
| Residence Characteristics | 2 | 2021 | 250 | 0.120 |
Why?
|
| Patients | 1 | 2014 | 34 | 0.120 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 129 | 0.120 |
Why?
|
| Caregivers | 1 | 2015 | 129 | 0.120 |
Why?
|
| Delivery of Health Care, Integrated | 3 | 2021 | 535 | 0.120 |
Why?
|
| Chloroquine | 1 | 2014 | 1 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2016 | 321 | 0.120 |
Why?
|
| Membrane Transport Proteins | 1 | 2014 | 4 | 0.120 |
Why?
|
| Reminder Systems | 1 | 2015 | 80 | 0.120 |
Why?
|
| Government Agencies | 1 | 2014 | 5 | 0.110 |
Why?
|
| Epidemiological Monitoring | 1 | 2014 | 25 | 0.110 |
Why?
|
| Public Sector | 1 | 2014 | 9 | 0.110 |
Why?
|
| Point-of-Care Systems | 1 | 2014 | 8 | 0.110 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2014 | 4 | 0.110 |
Why?
|
| Physician Assistants | 1 | 2014 | 7 | 0.110 |
Why?
|
| Prospective Studies | 4 | 2022 | 1279 | 0.110 |
Why?
|
| Endemic Diseases | 1 | 2013 | 1 | 0.110 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 181 | 0.110 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 487 | 0.110 |
Why?
|
| Mental Health | 1 | 2015 | 166 | 0.110 |
Why?
|
| Managed Care Programs | 1 | 2015 | 325 | 0.110 |
Why?
|
| Smoking Cessation | 1 | 2015 | 193 | 0.110 |
Why?
|
| Hospital Mortality | 2 | 2020 | 145 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 129 | 0.110 |
Why?
|
| Intensive Care Units | 2 | 2020 | 105 | 0.100 |
Why?
|
| Outpatients | 3 | 2021 | 110 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 710 | 0.100 |
Why?
|
| Lactones | 1 | 2012 | 11 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2014 | 247 | 0.100 |
Why?
|
| Coinfection | 1 | 2012 | 30 | 0.100 |
Why?
|
| Genotype | 3 | 2019 | 227 | 0.100 |
Why?
|
| Pneumonia | 1 | 2012 | 51 | 0.090 |
Why?
|
| Geography | 1 | 2011 | 39 | 0.090 |
Why?
|
| Censuses | 1 | 2011 | 31 | 0.090 |
Why?
|
| Radiography, Thoracic | 1 | 2011 | 19 | 0.090 |
Why?
|
| Immunoassay | 1 | 2010 | 8 | 0.090 |
Why?
|
| Lung | 1 | 2011 | 62 | 0.090 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2020 | 12 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 10 | 0.090 |
Why?
|
| Blood Specimen Collection | 2 | 2007 | 7 | 0.080 |
Why?
|
| Travel | 2 | 2007 | 10 | 0.080 |
Why?
|
| Surveys and Questionnaires | 3 | 2024 | 1321 | 0.080 |
Why?
|
| Health Behavior | 1 | 2011 | 360 | 0.080 |
Why?
|
| Health Maintenance Organizations | 1 | 2020 | 417 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 1213 | 0.080 |
Why?
|
| Costs and Cost Analysis | 1 | 2008 | 80 | 0.070 |
Why?
|
| Disease Management | 1 | 2009 | 135 | 0.070 |
Why?
|
| Models, Theoretical | 1 | 2008 | 70 | 0.070 |
Why?
|
| Child Health Services | 1 | 2009 | 113 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2008 | 381 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 455 | 0.070 |
Why?
|
| Datasets as Topic | 1 | 2025 | 20 | 0.060 |
Why?
|
| DNA, Protozoan | 2 | 2015 | 2 | 0.060 |
Why?
|
| Medical Records | 2 | 2016 | 100 | 0.060 |
Why?
|
| Sequence Analysis, DNA | 2 | 2015 | 30 | 0.060 |
Why?
|
| Urban Health | 2 | 2014 | 38 | 0.060 |
Why?
|
| Headache | 1 | 2022 | 14 | 0.050 |
Why?
|
| Myalgia | 1 | 2022 | 10 | 0.050 |
Why?
|
| Cough | 1 | 2022 | 22 | 0.050 |
Why?
|
| Seasons | 2 | 2014 | 105 | 0.050 |
Why?
|
| Georgia (Republic) | 1 | 2002 | 1 | 0.050 |
Why?
|
| Natural Language Processing | 1 | 2022 | 58 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2002 | 90 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2021 | 155 | 0.050 |
Why?
|
| Microscopy | 2 | 2012 | 5 | 0.050 |
Why?
|
| APACHE | 1 | 2021 | 11 | 0.050 |
Why?
|
| Health Surveys | 1 | 2002 | 260 | 0.050 |
Why?
|
| Intention to Treat Analysis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Algorithms | 1 | 2022 | 239 | 0.040 |
Why?
|
| Disease Progression | 1 | 2021 | 264 | 0.040 |
Why?
|
| Respiratory Tract Infections | 1 | 2021 | 50 | 0.040 |
Why?
|
| Hyperlipidemias | 1 | 2020 | 53 | 0.040 |
Why?
|
| Health Status | 1 | 2002 | 298 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2025 | 697 | 0.040 |
Why?
|
| Crustacea | 1 | 1998 | 1 | 0.040 |
Why?
|
| Pylorus | 1 | 1998 | 1 | 0.040 |
Why?
|
| Ganglia, Invertebrate | 1 | 1998 | 1 | 0.040 |
Why?
|
| Interferon-gamma Release Tests | 1 | 2018 | 1 | 0.040 |
Why?
|
| Mycobacterium tuberculosis | 1 | 2018 | 5 | 0.040 |
Why?
|
| Antitubercular Agents | 1 | 2018 | 9 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2010 | 354 | 0.040 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 172 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 188 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 132 | 0.040 |
Why?
|
| Epidemics | 1 | 2017 | 6 | 0.040 |
Why?
|
| Patient Dropouts | 1 | 2017 | 22 | 0.040 |
Why?
|
| Benchmarking | 1 | 2017 | 46 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 328 | 0.030 |
Why?
|
| Mutant Proteins | 1 | 2015 | 1 | 0.030 |
Why?
|
| Africa South of the Sahara | 1 | 2015 | 2 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2015 | 7 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2015 | 18 | 0.030 |
Why?
|
| Hypertension | 1 | 2020 | 504 | 0.030 |
Why?
|
| RNA, Ribosomal, 18S | 1 | 2014 | 1 | 0.030 |
Why?
|
| Point Mutation | 1 | 2015 | 6 | 0.030 |
Why?
|
| DNA, Ribosomal | 1 | 2014 | 2 | 0.030 |
Why?
|
| Hospitals, District | 1 | 2014 | 2 | 0.030 |
Why?
|
| Chemoprevention | 1 | 2014 | 12 | 0.030 |
Why?
|
| Research Design | 1 | 2017 | 376 | 0.030 |
Why?
|
| New Orleans | 1 | 2014 | 4 | 0.030 |
Why?
|
| Puerto Rico | 1 | 2014 | 5 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2014 | 72 | 0.030 |
Why?
|
| New York City | 1 | 2014 | 21 | 0.030 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2014 | 1 | 0.030 |
Why?
|
| RNA, Viral | 1 | 2014 | 64 | 0.030 |
Why?
|
| Organizational Objectives | 1 | 2014 | 18 | 0.030 |
Why?
|
| Disease Eradication | 1 | 2013 | 3 | 0.030 |
Why?
|
| Drug Utilization | 1 | 2014 | 128 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2012 | 215 | 0.020 |
Why?
|
| Sepsis | 1 | 2012 | 70 | 0.020 |
Why?
|
| Guidelines as Topic | 1 | 2009 | 40 | 0.020 |
Why?
|
| Survival Rate | 1 | 2009 | 260 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2007 | 4 | 0.020 |
Why?
|